Division of Endocrinology & Metabolism of Hospital de Clínicas-SEMPR, Federal University of Parana, Av. Agostinho Leão Júnior 285, Alto da Glória, Curitiba, Paraná, Cep: 80030-013, Brazil.
Curr Osteoporos Rep. 2012 Mar;10(1):48-55. doi: 10.1007/s11914-011-0083-y.
Transplantation is an established therapy for end-stage diseases of kidney, lung, liver, and heart among others. Osteoporosis and fragility fractures are serious complications of organ transplantation, particularly in the first post-transplant year. Many factors contribute to the pathogenesis of osteoporosis following organ transplantation. This review addresses the mechanisms of bone loss that occurs both in the early and late post-transplant periods, including the contribution of the immunosuppressive agents as well as the specific features to bone loss after kidney, lung, liver, cardiac, and bone marrow transplantation. Prevention and treatment for osteoporosis in the transplant recipient are also discussed.
移植是治疗肾脏、肺部、肝脏和心脏等终末期疾病的一种成熟疗法。骨质疏松症和脆性骨折是器官移植的严重并发症，特别是在移植后的第一年。许多因素导致器官移植后发生骨质疏松症。这篇综述讨论了发生在移植后早期和晚期的骨质流失机制，包括免疫抑制剂的作用以及肾、肺、肝、心脏和骨髓移植后骨质流失的特定特征。还讨论了移植受者骨质疏松症的预防和治疗。
